Navigation Links
Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference
Date:5/18/2012

NEW YORK, May 18, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that Dr. Daniel G. Chain, the company's chairman and CEO, will be presenting at the Seventh Annual Neurotech Investing and Partnering Conference.

(Logo:  http://photos.prnewswire.com/prnh/20111214/NY22484LOGO)

The title of Dr. Chain's presentation is "Prefibrillar Tau Neoepitopes Offer Attractive Targets for Active and Passive Immunotherapy." His presentation will take place on May 21st at the Intercontinental Hotel in Boston from 10:15-11:30 AM (EDT), as part of the session entitled "Alzheimer's and Cognitive Disorders."   

"Intellect Neurosciences is at the forefront of Alzheimer's research, with a rich pipeline and intellectual property portfolio and licensed products in late-stage clinical development," said Dr. Chain.  "We embrace opportunities like this one and realize they are essential toward raising additional awareness of our technology, our work in developing ground-breaking treatments for Alzheimer's and other devastating neurodegenerative diseases."

About The Neurotech Investing and Partnering Conference

The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.  This market-defining conference features keynotes on the state of the neurotech industry, cutting edge company presentations, leading translational research projects and panel discussions on a comprehensive selection of neurotech topics.

About Intellect Neurosciences

Intellect Neurosciences, Inc., develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.

The company currently is developing products based on three platform technologies: ANTISENILIN® is Intellect's Alzheimer's beta amyloid monoclonal antibody platform technology, which underlies a product in Phase 3 clinical trials and is licensed to major pharmaceutical companies. ANTISENILIN also underlies IN-N01, a humanized monoclonal antibody being developed by the company as an antibody dug conjugate (ADC). IN-N01-OX2 is the first candidate to emerge from the company's CONJUMAB-A platform technology, which is based on a novel application of antibody drug conjugates in which the antibody is chemically conjugated to a small molecule (OX2) that has potent neuroprotective properties both as an antioxidant and inhibitor of protein aggregation. RECALL-VAX is a therapeutic vaccine technology that underlies three preclinical drug candidates, RV01 and RVO2, which target beta amyloid and delta tau protein, respectively, and RVO3, which is a combination of the two.

The company recently licensed OX1, a small molecule multimodal antioxidant, to ViroPharma, Inc. for Friedreich's Ataxia and other neurodegenerative diseases. For more information, please visit www.intellectns.com.

Safe Harbor Statement Regarding Forward-­Looking Statements:

The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-­‐looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-­‐looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-­‐128226), filed on October 13, 2011, and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012, which was filed on May 14, 2012.

Contact:
Jules Abraham
JQA Partners, LLC
917-885-7378
jabraham@jqapartners.com


'/>"/>
SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Intellect Neurosciences Adds Two New Tau Programs to its Alzheimers Disease Development Pipeline
2. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
3. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
4. Intellectual Property Lawyer Available for Comment on Recent Supreme Court Ruling
5. Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum
6. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
7. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
8. iPierian Expands Leadership Team With Experienced Business Development and Intellectual Property Executives
9. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
10. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
11. BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 23, 2017 , ... Federal funding for basic and applied scientific research ... medical and other vital technologies — deserves continued support, say leaders of SPIE, ... community today in responding to the President’s budget request for Fiscal Year 2018. , ...
(Date:5/23/2017)... ... 2017 , ... Firmex today announced the general ... for organizations to send and gather large files and confidential documents beyond the ... size limitations. , Using the same market-tested infrastructure as Firmex’s flagship Virtual ...
(Date:5/23/2017)... ... 2017 , ... Genedata, a leading provider of advanced software ... a strong presence at Bio-IT World Conference & Expo 2017 in Boston, MA. ... all attendees to view posters on the entire range of Genedata software ...
(Date:5/23/2017)... ... , ... Vortex Biosciences , provider of circulating tumor cell (CTC) capture ... using Vortex microfluidic technology ” in Nature Precision Oncology on May 8th. The ... and Dr. Matthew Rettig at the University of California, Los Angeles. The publication describes ...
Breaking Biology Technology:
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):